Nifty Pharma Index Underperforms in 2025: A Stock-Picker’s Market

The year 2025 was not kind to the Nifty Pharma index, which slipped nearly 3% due to US pricing pressure, regulatory worries, and trade jitters. However, beneath the gloom, a few pharma stocks quietly played hero, delivering double-digit gains and rewarding investors who dared to look beyond the index.

Top Performing Pharma Stocks

Some of the top performing pharma stocks in 2025 included:

Laurus Labs: A Strong Performer

Laurus Labs delivered a strong second quarter performance, beating estimates across all metrics. The company guided its ARV business to reach Rs 2,500 crore for fiscal 2026, while continuing to invest in animal health and crop science CDMO capabilities. Adding to the momentum, Laurus reported robust export data in November 2025, reinforcing its growth outlook.

Glenmark Pharmaceuticals: A Return to High-Growth Trajectory

Glenmark Pharmaceuticals secured major licensing deals during the year and signaled a return to a high-growth trajectory. The company also reported strong export data in November 2025.

Torrent Pharmaceuticals: Limited Exposure to US Generic Pricing Pressure

Torrent Pharmaceuticals stood out for its limited exposure to US generic pricing pressure, which shielded it from one of the sector’s biggest headwinds. The company maintained consistent earnings delivery and demonstrated strong margin stability.

Sai Life Sciences: Strong CDMO Performance

Sai Life Sciences delivered a strong CDMO performance in the second quarter. The company also deepened its capabilities by investing in complex peptide synthesis and antibody-drug conjugates.

Neuland Labs: Strong All-Round Beat

Neuland Labs posted a strong all-round beat in quarter ended September, with Ebitda hitting an all-time high. The company’s superior product mix drove profitability, and it also had a robust export data in November 2025.

Reasons for Nifty Pharma’s Underperformance

The Nifty Pharma index was down due to a couple of reasons, including persistent US generic pricing pressure, global tariff and trade uncertainty, which ultimately hurt export visibility. Another key reason was earnings disappointment in index heavyweights and regulatory overhang, which capped valuation re-rating.

For investors looking to invest in the pharma sector, it’s essential to do their research and stock market analysis to identify potential winners. With the right strategy and a long-term perspective, investors can navigate the challenges in the pharma sector and reap rewards.

Conclusion

In conclusion, the Nifty Pharma index underperformed in 2025 due to various challenges. However, some pharma stocks delivered impressive gains, highlighting the importance of a stock picker’s market. As investors look to the future, it’s crucial to stay informed and adapt to the changing landscape of the pharma sector.